These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32725789)

  • 1. Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.
    Lee SH; Park W; Won Lee S; Kim HA; Choe JY; Lee SH; Lee SS; Park SH; Park MC; Sheen DH; Lee HS; Lee YA; Lee Y; Kim TH
    Int J Rheum Dis; 2020 Aug; 23(9):1175-1183. PubMed ID: 32725789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.
    Rudwaleit M; Claudepierre P; Kron M; Kary S; Wong R; Kupper H
    Arthritis Res Ther; 2010; 12(2):R43. PubMed ID: 20230622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study.
    Sunar I; Ataman S; Nas K; Kilic E; Sargin B; Kasman SA; Alkan H; Sahin N; Cengiz G; Cuzdan N; Gezer IA; Keskin D; Mülkoğlu C; Resorlu H; Bal A; Duruöz MT; Küçükakkaş O; Yurdakul OV; Melikoglu MA; Aydın Y; Ayhan FF; Bodur H; Calis M; Capkın E; Devrimsel G; Gok K; Hizmetli S; Kamanlı A; Keskin Y; Kocabas H; Kutluk O; Şen N; Şendur OF; Tekeoğlu I; Tolu S; Toprak M; Tuncer T
    Rheumatol Int; 2020 Feb; 40(2):283-294. PubMed ID: 31773391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.
    Mease PJ; Van den Bosch F; Sieper J; Xia Y; Pangan AL; Song IH
    J Rheumatol; 2017 May; 44(5):599-608. PubMed ID: 28298558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
    Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
    Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.
    Braun J; Rudwaleit M; Kary S; Kron M; Wong RL; Kupper H
    Rheumatology (Oxford); 2010 Aug; 49(8):1578-89. PubMed ID: 20448079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A psychometric analysis of outcome measures in peripheral spondyloarthritis.
    Turina MC; Ramiro S; Baeten DL; Mease P; Paramarta JE; Song IH; Pangan AL; Landewé R
    Ann Rheum Dis; 2016 Jul; 75(7):1302-7. PubMed ID: 26245756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colour Doppler ultrasonography can be used to detect the changes of sacroiliitis and peripheral enthesitis in patients with ankylosing spondylitis during adalimumab treatment.
    Hu Z; Xu M; Wang Q; Qi J; Lv Q; Gu J
    Clin Exp Rheumatol; 2015; 33(6):844-50. PubMed ID: 26321072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan.
    Kobayashi S; Kashiwagi T; Kimura J
    Mod Rheumatol; 2019 Nov; 29(6):1007-1012. PubMed ID: 30221573
    [No Abstract]   [Full Text] [Related]  

  • 14. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe.
    Szántó S; Poór G; Opris D; Iaremenko O; Procházková L; Kuuse R; Nagy O; Chernyshov V; Géher P
    J Comp Eff Res; 2016 Aug; 5(5):475-85. PubMed ID: 27417564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
    Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
    Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI.
    Palominos PE; de Campos APB; Ribeiro SLE; Xavier RM; Xavier JW; de Oliveira FB; Guerra B; Saldanha C; Mancuso ACB; Kohem CL; Gasparin AA; Sampaio-Barros PD
    Adv Rheumatol; 2019 Jun; 59(1):23. PubMed ID: 31208465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
    Schett G; Baraliakos X; Van den Bosch F; Deodhar A; Østergaard M; Gupta AD; Mpofu S; Fox T; Winseck A; Porter B; Shete A; Gensler LS
    J Rheumatol; 2021 Aug; 48(8):1251-1258. PubMed ID: 33722947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.